Brief: Immunovia And Global Pharmaceutical Company Agree On Early Termination Of Lung Cancer Collaboration
April 8 (Reuters) - Immunovia AB (publ) IMMNOV.ST :
* IMMUNOVIA AND GLOBAL PHARMACEUTICAL COMPANY AGREE ON EARLY
TERMINATION OF LUNG CANCER COLLABORATION
* IMMUNOVIA'S OWN EARLY DETECTION PROGRAM IN LUNG CANCER
CONTINUES
AS PLANNED
* IMMUNOVIA'S STUDY IS ON TRACK AND WILL BE FINISHED IN Q2
2020 AS
PLANNED
Source text for Eikon: ID:nWkrbD2nsP
Further company coverage: IMMNOV.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Immunovia AB (publ)
See all newsBrief: Immunovia Publishes Data On Pancreasure In Hereditary, Familial High-Risk Individuals
Brief: Immunovia To Carry Out Rights Issue Of About SEK 63 Million
Sweden's Immunovia Q2 sales rise on PancreaSure test uptake
Brief: Immunovia Reports Q2 Operating Loss Of SEK 22.8 Million
Brief: PancreaSure Achieves 88% Sensitivity In Immunovia Study